Literature DB >> 2122316

Endothelin in renal failure.

A N Warrens1, M J Cassidy, K Takahashi, M A Ghatei, S R Bloom.   

Abstract

Endothelin is a 21-residue peptide vasoconstrictor produced by endothelium. Using a radioimmunoassay, endothelin values were measured in four groups of individuals: normal controls (0.54 +/- 0.12 pmol/l, n = 20); undialysed patients with chronic renal failure (CRF) (0.82 +/- 0.13 pmol/l, n = 38); chronic renal failure patients on continuous ambulatory peritoneal dialysis (CAPD) (2.81 +/- 0.63 pmol/l, n = 20); and patients with CRF on haemodialysis (HD) (4.52 +/- 1.21 pmol/l, n = 14). The endothelin values were significantly greater in undialysed patients with CRF when compared with controls (P less than 0.001) and significantly greater in both dialysis groups when compared with controls and the undialysed CRF group (P much less than 0.001). The difference between the two dialysis groups was not significant (P = 0.07). There was no correlation between endothelin and serum creatinine, mean arterial pressure, presence of chronic hypertension and/or diabetes, use of calcium-channel blockers and/or ACE inhibitors, or primary renal diagnostic category. A single haemodialysis session had no significant effect on endothelin values in the ten patients in whom this was assessed. Fast protein liquid chromatography (FPLC) appeared to confirm that the molecular species found in chronic renal failure were the same as those found in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122316     DOI: 10.1093/ndt/5.6.418

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

Review 1.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

2.  Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis?

Authors:  E M El-Shafey; G F El-Nagar; M F Selim; H A El-Sorogy; A A Sabry
Journal:  Clin Exp Nephrol       Date:  2008-06-21       Impact factor: 2.801

3.  Hepatic effects of endothelin. Receptor characterization and endothelin-induced signal transduction in hepatocytes.

Authors:  C R Gandhi; R H Behal; S A Harvey; T A Nouchi; M S Olson
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

4.  Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat.

Authors:  J P Cristol; T D Warner; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

5.  Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.

Authors:  Ivanka Mikulić; József Petrik; Kresimir Galesić; Zeljko Romić; Ivana Cepelak; Monika Zeljko-Tomić
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

6.  Endothelin-1 in children with chronic renal failure.

Authors:  I Blazy; M Déchaux; M Charbit; D Brocart; J C Souberbielle; M F Gagnadoux; F Guillot; C Sachs
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

7.  Plasma atrial natriuretic peptide and endothelin levels in acute poststreptococcal glomerulonephritis.

Authors:  S Ozdemir; U Saatçi; N Beşbaş; A Bakkaloglu; S Ozen; Z Koray
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

Review 8.  Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease.

Authors:  G Noll; R R Wenzel; T F Lüscher
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.